First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.
A patient with pulmonary metastasis of colon cancer was treated with artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4 cancer antigen. The patient was vaccinated with MAGE-A4-H/K-HELP combined with OK432 and Montanide ISA-51. There were no severe side-effects except for a skin reaction at the injection site. MAGE-A4-H/K-HELP induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and carcinoembryonic antigen tumor marker were significantly decreased in the final diagnosis. This is the first report that artificially synthesized MAGE-A4-H/K-HELP induces Th1-dependent cellular and humoral immune responses in a human cancer patient.
First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Norihiko
N
Takahashi
Takayuki
T
Ohkuri
Shigenori
S
Homma
Junya
J
Ohtake
Daiko
D
Wakita
Yuji
Y
Togashi
Hidemitsu
H
Kitamura
Satoru
S
Todo
Takashi
T
Nishimura
D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D011379:Prognosis; D018417:Th1 Cells / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; C095204:MAGEA4 protein, human; D009363:Neoplasm Proteins